BioWorld

Dec. 3, 2003

View Archived Issues

Maxim's Preclinical Cancer Work Nets Potential $27M Myriad Deal

Maxim Pharmaceuticals Inc. nailed down a potential $27 million licensing deal centered on its apoptosis-inducing cancer compounds with Myriad Genetics Inc. (BioWorld Today) Read More

Stressgen, Roche Add New Indications To Collaboration

Read More

Europeans Continue Struggling To Blend The Colors Of Biotech

Read More

Incoming EU Members Want Their Piece Of The Biotech Pie

Read More

Sepracor's Inhaled Xopenex Positive In Phase III Studies

Read More

Other News To Note

Read More